Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group.
about
Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimensGranulocyte-macrophage colony-stimulating factor as an immune-based therapy in HIV infection.Metabolic effects of indinavir in healthy HIV-seronegative menABT-378, a highly potent inhibitor of the human immunodeficiency virus proteaseHIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitusOngoing trials in HIV protease inhibitors.Joint modeling of longitudinal and survival data with missing and left-censored time-varying covariates.Use of observational data in evaluating treatments: antiretroviral therapy and HIV.Long-term survival in HIV positive patients with up to 15 Years of antiretroviral therapyThe effect of combined antiretroviral therapy on the overall mortality of HIV-infected individualsThe use of combination antiretroviral therapy in HIV-infected patients.Using marginal structural measurement-error models to estimate the long-term effect of antiretroviral therapy on incident AIDS or deathEffect of HAART on incident cancer and noncancer AIDS events among male HIV seroconverters.HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications.Accelerated publication versus usual publication in 2 leading medical journalsDiscontinuation rates for protease inhibitor regimens containing ritonavir 600 mg versus ritonavir 400 mg plus saquinavir 400 mg.Oropharyngeal candidiasis in the era of antiretroviral therapyEvaluating supervised HAART in late-stage HIV among drug users: a preliminary report.Patterns of changes in human immunodeficiency virus type 1 V3 sequence populations late in infection.When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.Effect of a protease inhibitor-induced genetic bottleneck on human immunodeficiency virus type 1 env gene populations.Palliative care for HIV disease in the era of highly active antiretroviral therapy.HIV-1 protease inhibitors.Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study GroupRitonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavirNeurological and psychiatric adverse effects of antiretroviral drugs.Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection.A simulation study of finite-sample properties of marginal structural Cox proportional hazards models.The parametric g-formula to estimate the effect of highly active antiretroviral therapy on incident AIDS or death.Characteristics of HIV infection/AIDS in KoreaEvolution of HIV treatment guidelines in high- and low-income countries: converging recommendationsOngoing trials of immune-based therapies for HIV infection in adults.What are the perceived advantages and disadvantages of non-nucleoside reverse transcriptase inhibitors as first-line therapy?Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement.HIV-1 protease inhibitors in development.Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equalEffectiveness of efavirenz-based regimens in young HIV-infected children treated for tuberculosis: a treatment option for resource-limited settings.A multiple-site-specific heteroduplex tracking assay as a tool for the study of viral population dynamics.Pathogenesis and treatment of human immunodeficiency virus lipodystrophy
P2860
Q24534391-CF76B21C-5F99-4A99-BE8B-6BCDE2618E06Q24814373-1B5C28F4-9479-47A6-AE8B-16E9A5575EB8Q28366603-78302892-D8F1-4118-94AA-3DC721BE6807Q28369297-96B93AD8-D910-4B04-AF7B-90F514DD8A90Q28582686-F1592537-0782-4199-AEE9-682FBB7B7855Q30327423-958CB8FA-FDD3-494F-B283-772A9376E7A8Q30832318-9DF9BD0F-06EB-407F-87CC-61F577EC3E31Q30969932-BDC4CB26-4519-4A24-AEF7-3C219827368DQ31106702-F8453209-D855-4BEB-94EF-467F37994856Q33505475-AE1C37E5-9A01-419D-9847-16A5F1D3CFF2Q33543115-A36F9073-93ED-45FC-9F19-7CAE6140FB86Q33566815-58E82574-06E2-47B3-9D51-657E450DC835Q33585427-C19977AE-E60C-443F-ABF3-9A89A176B5EAQ33604216-EFA165A2-231C-4734-9DFE-2457ED2E9363Q33609417-E26D3223-7468-4DBE-90A7-708849A7672CQ33735372-1CF41259-9BA7-4D1F-B728-60DA66F1DAE3Q33746435-8E792522-A1E7-4163-BA91-6D2E3188D8EDQ33803069-1526E39A-90FA-4C5E-8D58-EB9D1AED4108Q33874171-D65DD8AB-7197-4B68-8A94-AFC137AABA51Q33876261-C2176F13-0F19-4CF0-B99F-A738EE07880BQ33912028-64075207-E92B-47FD-8303-2558E76DBB6FQ33944367-6826F3CA-B907-4768-A1FF-54DFF10775D4Q33946920-9531BAD6-C599-4DF7-85B8-AACCC51F1CECQ33981058-6ADC5AF5-9124-4E00-94AA-D93F31A12537Q33983571-E17A32A4-24EF-4301-9577-D9D580AFCF6CQ33983801-5A3E5AF9-2FF8-4EEB-89FB-54B9348D03B1Q34039419-5A92C92E-2CFD-498B-8D4D-B8DA402CE2F4Q34084316-715F6BB8-19C4-4FFC-B8FA-F7077B041AA6Q34227946-4A00D8F1-7E69-49ED-9882-EC623F3D64DEQ34229301-7F43626C-B153-4C1A-93CB-6426B99AECACQ34288327-ABE6530E-F89F-4D34-AA4E-75EF4EECDA43Q34321843-1E4F9B49-0D9E-4661-8633-37FC7D902102Q34451967-B6E212B1-DEC7-41AE-8416-5D91E7353D49Q34459331-BA31F034-135C-4990-A2CE-67C55B6406ABQ34521994-0E1679F3-2DCB-45A6-AC90-4BE84CE322E5Q34544671-28266318-2C9C-4383-B44C-715C49003023Q34546056-7C464E54-C079-4D1F-83BB-DE0233402DC4Q34571594-C309C165-6B4F-440A-AB6E-E0FE5FDC4FE6Q34588592-958D6F68-7788-4550-9A7B-3DB1B3013A61Q34639290-961A8EA3-2F20-4920-B8FB-EC13985D67D6
P2860
Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Randomised placebo-controlled ...... Disease Ritonavir Study Group.
@en
Randomised placebo-controlled ...... Disease Ritonavir Study Group.
@nl
type
label
Randomised placebo-controlled ...... Disease Ritonavir Study Group.
@en
Randomised placebo-controlled ...... Disease Ritonavir Study Group.
@nl
prefLabel
Randomised placebo-controlled ...... Disease Ritonavir Study Group.
@en
Randomised placebo-controlled ...... Disease Ritonavir Study Group.
@nl
P2093
P1433
P1476
Randomised placebo-controlled ...... Disease Ritonavir Study Group.
@en
P2093
A Potthoff
D W Cameron
M Heath-Chiozzi
P304
P356
10.1016/S0140-6736(97)04161-5
P407
P577
1998-02-01T00:00:00Z